Phase 3 Clinical Trials With Primary Completion Dates in January 2016
This is a list of Phase 3 trials with primary completion dates in January 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals, Inc. | 2016-01-01 | Phase 3 | NCT02274766 | Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia |
| CLVS | Clovis Oncology, Inc. | 2016-01-01 | Phase 3 | NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| DERM | Dermira, Inc. | 2016-01-01 | Phase 3 | NCT02326272 | A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) |
| KERX | Keryx Biopharmaceuticals, Inc. | 2016-01-01 | Phase 3 | NCT02268994 | KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD |
| MMSI | Merit Medical Systems, Inc. | 2016-01-01 | Phase 3 | NCT02159898 | EndoMAXX EVT Compared to EndoMAXX |
| ONTX | Onconova Therapeutics, Inc. | 2016-01-01 | Phase 3 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |